Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesSexual / hormonalHCG (Human Chorionic Gonadotropin)

HCG (Human Chorionic Gonadotropin)

/ Glycoprotein heterodimer — α-subunit (common to LH, FSH, TSH) plus hCG-specific β-subunit
TIER 1 · ClinicalN = 0 · TESTING PENDINGMW 37500.00 g·mol⁻¹

ALIAS · HCG · Pregnyl (trade) · Novarel (trade) · Ovidrel (recombinant) · Human Chorionic Gonadotropin

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · 37500.00CLASS · Glycoprotein heterodimer — α-subunit (common to LH, FSH, TSH) plus hCG-specific β-subunitCATEGORY · Sexual / hormonal

Tier 1. Decades-old approved product across multiple indications: ovulation induction in IVF, treatment of hypogonadotropic hypogonadism in men, prepubertal cryptorchidism, and fertility preservation during gonadotoxic therapy. Multiple FDA-approved formulations including urinary-derived (Pregnyl, Novarel) and recombinant (Ovidrel).

§ B · Mechanism of action

hCG binds the LH/CG receptor (LHCGR) on Leydig cells and ovarian theca/granulosa cells with biological activity similar to luteinizing hormone but a substantially longer plasma half-life. In men, hCG drives Leydig cell testosterone production while preserving spermatogenesis (in contrast to exogenous testosterone, which suppresses it). In women, hCG triggers ovulation as the LH-surge mimic in IVF and supports the corpus luteum in early pregnancy.

§ C · Human clinical evidence

Tier 1. Long-standing approved use across multiple endocrine and fertility indications.

§ D · Primary literature
PubMed12107212Liu PY et al.A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency · Journal of Clinical Endocrinology & Metabolism · human-phase-2rhCG raised serum testosterone in older men with partial androgen deficiency but did not significantly improve muscle strength or physical function vs placebo over the trial period.Limitations: Modest sample size; short duration; functional endpoints may have been underpowered.2002
PubMed15713727Coviello AD et al.Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression · Journal of Clinical Endocrinology & Metabolism · human-phase-2Adjunct low-dose hCG (125-500 IU) preserved intratesticular testosterone during exogenous testosterone suppression — mechanistic basis for hCG co-administration in TRT.Limitations: Single-centre, healthy young volunteers; short duration; surrogate endpoint (intratesticular T).2005
§ F · Safety signal

Well-characterised across decades of clinical use. Ovarian hyperstimulation syndrome is the main acute concern in female fertility use. In men, gynecomastia from peripheral testosterone-to-estradiol aromatisation is the most common dose-limiting adverse event.

§ H · Regulatory status

Regulatory status

FDA status:
FDA-approved
§ I · Notable gaps and controversies

Vendor-sold 'HCG' for non-medical purposes (e.g. weight-loss protocols associated with the Simeons regimen) lacks any evidence base — the HCG diet has been examined in multiple controlled trials and produces no weight-loss benefit beyond the very-low-calorie diet itself.